Oral supplementation of EVNol SupraBio, a full spectrum tocotrienol/tocopherol complex derived from Malaysian certified sustainable palm oil, significantly improved nerve growth factor and nerve conduction velocities in the nerves of diabetic peripheral neuropathy (DPN) patients, as demonstrated in a Phase II study published in the journal Nutrients. This multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial was conducted by researchers from Jeffrey Cheah School of Medicine and Health Sciences, Monash University- Malaysia Campus.

 

In the study, 80 eligible participants were randomized into two groups. One received 200mg EVNol SupraBio (encapsulated in a softgel branded as Tocovid SupraBio) twice a day. The other received a placebo twice a day. The nerve conduction velocity test was carried out on three nerves: median, sural and tibial. This test measures how fast the nerves could send important signals. In DPN patients, loss of large myelinated fibers leads to slowing of nerve conduction velocity. After 8 weeks of supplementation, the results showed that there was a highly significant improvement in nerve conduction velocities of all nerves (median nerve: +1.25 m/s; sural nerve: +1.60 m/s; tibial nerve: +0.75 m/s) in participants receiving EVNol SupraBio as compared with the placebo.

 

Chronic hyperglycemia increases oxidative stress, activates inflammatory pathways and reduces nerve growth factor (NGF) among diabetic patients, which contribute to DPN development. As a potent antioxidant and anti-inflammatory agent, it was thought that EVNol SupraBio would improve DPN by acting on oxidative stress and chronic inflammation. However, the result of this study showed the serum biomarkers reflecting oxidative stress (MDA) and inflammatory activities (VCAM-1 and TNFR-1) remained similar between the 2 supplementation groups.

Surprisingly, this study discovered that serum NGF is significantly elevated at eight weeks post-intervention among the participants on EVNol SupraBio’s supplementation compared with those who took the placebo. This increase in serum NGF reflects the reversal of neuronal injuries as well as the restoration of nerve function, and thus suggests that EVNol SupraBio most probably acts through the pathway involving NGF,  not the oxidative stress or chronic inflammatory pathogenesis, to improve DPN.

 

The researchers subsequently hypothesized that EVNol SupraBio’s ability to significantly improve NGF could be the possible alternative pathway in enhancing nerve conduction velocities, as shown in this particular human trial. This finding is fascinating as no other study in the past has demonstrated that tocotrienol-rich Vitamin E can increase serum NGF level among the diabetic population, and correlated it to improvements in terms of peripheral nerve conduction velocities. 

 

SEE ALSO  Is palm oil similar to palm kernel oil?

ExcelVite Business Development Manager Bryan See explained the significance of this study: “DPN is one of the most common diabetic complications that impairs the quality of life and causes significant morbidity as well as mortality. Given that approximately 50 percent of adults with diabetes will be affected by peripheral neuropathy in their lifetime, it is crucial to find an intervention that could help these patients. Our clinical work on EVNol SupraBio in diabetic complications started in 2016. To date, four clinical papers have been published, reporting the efficacy of this patented bioenhanced natural full-spectrum palm tocotrienol complex as a complementary therapy for diabetic nephropathy and DPN. My colleagues and I are extremely excited with this novel finding in DPN patients. We are now planning a new clinical trial, a dose-dependent study of EVNol SupraBio in diabetic complications. Together, it underscores the importance of EVNol SupraBio as a potential natural phytonutrient in managing diabetes complications for healthy kidney and nerve functions.”

 

Related Excelvite clinical papers 

 

The statements in the above article have not been evaluated by the Food and Drug Administration. They are not intended to diagnose, treat, cure or prevent any disease.

Share This